TY - JOUR
T1 - Strategies to decrease inequalities in cancer therapeutics, care and prevention
T2 - Proceedings on a conference organized by the Pontifical Academy of Sciences and the European Academy of Cancer Sciences, Vatican City, February 23–24, 2023
AU - Ringborg, Ulrik
AU - von Braun, Joachim
AU - Celis, Julio
AU - Baumann, Michael
AU - Berns, Anton
AU - Eggermont, Alexander
AU - Heard, Edith
AU - Heitor, Manuel
AU - Chandy, Mammen
AU - Chen, Chien Jen
AU - Costa, Alberto
AU - De Lorenzo, Francesco
AU - De Robertis, Edward M.
AU - Dubee, Frederick Charles
AU - Ernberg, Ingemar
AU - Gabriel, Mariya
AU - Helland, Åslaug
AU - Henrique, Rui
AU - Jönsson, Bengt
AU - Kallioniemi, Olli
AU - Korbel, Jan
AU - Krause, Mechthild
AU - Lowy, Douglas R.
AU - Michielin, Olivier
AU - Nagy, Peter
AU - Oberst, Simon
AU - Paglia, Vincenzo
AU - Parker, M. Iqbal
AU - Ryan, Kevin
AU - Sawyers, Charles L.
AU - Schüz, Joachim
AU - Silkaitis, Katherine
AU - Solary, Eric
AU - Thomas, David
AU - Turkson, Peter
AU - Weiderpass, Elisabete
AU - Yang, Huanming
N1 - Publisher Copyright:
© 2023 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
PY - 2024/2/1
Y1 - 2024/2/1
N2 - Analyses of inequalities related to prevention and cancer therapeutics/care show disparities between countries with different economic standing, and within countries with high Gross Domestic Product. The development of basic technological and biological research provides clinical and prevention opportunities that make their implementation into healthcare systems more complex, mainly due to the growth of Personalized/Precision Cancer Medicine (PCM). Initiatives like the USA-Cancer Moonshot and the EU-Mission on Cancer and Europe's Beating Cancer Plan are initiated to boost cancer prevention and therapeutics/care innovation and to mitigate present inequalities. The conference organized by the Pontifical Academy of Sciences in collaboration with the European Academy of Cancer Sciences discussed the inequality problem, dependent on the economic status of a country, the increasing demands for infrastructure supportive of innovative research and its implementation in healthcare and prevention programs. Establishing translational research defined as a coherent cancer research continuum is still a challenge. Research has to cover the entire continuum from basic to outcomes research for clinical and prevention modalities. Comprehensive Cancer Centres (CCCs) are of critical importance for integrating research innovations to preclinical and clinical research, as for ensuring state-of-the-art patient care within healthcare systems. International collaborative networks between CCCs are necessary to reach the critical mass of infrastructures and patients for PCM research, and for introducing prevention modalities and new treatments effectively. Outcomes and health economics research are required to assess the cost-effectiveness of new interventions, currently a missing element in the research portfolio. Data sharing and critical mass are essential for innovative research to develop PCM. Despite advances in cancer research, cancer incidence and prevalence is growing. Making cancer research infrastructures accessible for all patients, considering the increasing inequalities, requires science policy actions incentivizing research aimed at prevention and cancer therapeutics/care with an increased focus on patients' needs and cost-effective healthcare.
AB - Analyses of inequalities related to prevention and cancer therapeutics/care show disparities between countries with different economic standing, and within countries with high Gross Domestic Product. The development of basic technological and biological research provides clinical and prevention opportunities that make their implementation into healthcare systems more complex, mainly due to the growth of Personalized/Precision Cancer Medicine (PCM). Initiatives like the USA-Cancer Moonshot and the EU-Mission on Cancer and Europe's Beating Cancer Plan are initiated to boost cancer prevention and therapeutics/care innovation and to mitigate present inequalities. The conference organized by the Pontifical Academy of Sciences in collaboration with the European Academy of Cancer Sciences discussed the inequality problem, dependent on the economic status of a country, the increasing demands for infrastructure supportive of innovative research and its implementation in healthcare and prevention programs. Establishing translational research defined as a coherent cancer research continuum is still a challenge. Research has to cover the entire continuum from basic to outcomes research for clinical and prevention modalities. Comprehensive Cancer Centres (CCCs) are of critical importance for integrating research innovations to preclinical and clinical research, as for ensuring state-of-the-art patient care within healthcare systems. International collaborative networks between CCCs are necessary to reach the critical mass of infrastructures and patients for PCM research, and for introducing prevention modalities and new treatments effectively. Outcomes and health economics research are required to assess the cost-effectiveness of new interventions, currently a missing element in the research portfolio. Data sharing and critical mass are essential for innovative research to develop PCM. Despite advances in cancer research, cancer incidence and prevalence is growing. Making cancer research infrastructures accessible for all patients, considering the increasing inequalities, requires science policy actions incentivizing research aimed at prevention and cancer therapeutics/care with an increased focus on patients' needs and cost-effective healthcare.
KW - cancer prevention
KW - cancer therapeutics/care
KW - healthcare
KW - inequalities
KW - science policy
KW - translational cancer research
UR - http://www.scopus.com/inward/record.url?scp=85182823480&partnerID=8YFLogxK
U2 - 10.1002/1878-0261.13575
DO - 10.1002/1878-0261.13575
M3 - Article
C2 - 38135904
AN - SCOPUS:85182823480
SN - 1574-7891
VL - 18
SP - 245
EP - 279
JO - Molecular Oncology
JF - Molecular Oncology
IS - 2
ER -